A naukri.com initiative
Bioengineer
4d
193
Image Credit: Bioengineer
Psilocybin Enters Gastroenterology: Pioneering Psychedelic Trial Targets Treatment-Resistant IBS
- Dr. Erin E. Mauney pioneers a clinical trial using psilocybin to treat treatment-resistant IBS, bridging mental health, neurobiology, and gastroenterology.
- The study aims to understand how psilocybin affects interoception and gut-brain communication pathways in IBS patients.
- Dr. Mauney's research suggests that trauma-induced somatic encoding may contribute to IBS and explores psilocybin's ability to disrupt maladaptive neural patterns.
- Her work integrates patient-reported outcomes, qualitative narratives, and fMRI data to evaluate and model functional somatic syndromes.
- By unlocking somatically encoded trauma, Dr. Mauney's research envisions sustained functional recovery for IBS patients.
- Her study challenges clinical norms by proposing psychedelic therapy for psychological and physiological recalibration, not just symptom suppression.
- Dr. Mauney emphasizes building authentic relationships with patients and promoting patient-centered care in her research approach.
- She looks towards wider accessibility of psychedelic treatments and envisions their integration into standard clinical practice for IBS and beyond.
- The study prompts considerations for applying trauma-informed psychedelic interventions in other treatment-resistant medical conditions.
- Dr. Mauney's work signifies a transformative shift in gastroenterology and highlights the interconnectedness of mind and body in treating complex illnesses holistically.
Read Full Article
11 Likes
For uninterrupted reading, download the app